（Secondary Publication）移植前のカルシウム受容体作動薬の使用および投与量の情報は腎移植後の三次性副甲状腺機能亢進症の予測精度を向上させる：単施設後ろ向きコホート研究
Saved in:
| Published in | 移植 Vol. 60; no. 1; pp. 25 - 37 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | Japanese |
| Published |
一般社団法人 日本移植学会
2025
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0578-7947 2188-0034 |
| DOI | 10.11386/jst.60.1_25 |
Cover
| Author | 佐藤 哲彦 鳴海 俊治 一森 敏弘 姫野 智紀 岡田 学 平光 高久 後藤 憲彦 渡井 至彦 長谷川 雄基 二村 健太 |
|---|---|
| Author_xml | – sequence: 1 fullname: 佐藤 哲彦 organization: 日本赤十字社愛知医療センター名古屋第二病院 糖尿病内分泌内科 – sequence: 1 fullname: 渡井 至彦 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 長谷川 雄基 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 一森 敏弘 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 平光 高久 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 二村 健太 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 岡田 学 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 鳴海 俊治 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 後藤 憲彦 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 – sequence: 1 fullname: 姫野 智紀 organization: 日本赤十字社愛知医療センター名古屋第二病院 移植外科・移植内科 |
| BookMark | eNo9kctu01AQho9QkQilOx6AF3A5x3Z8kdigiptUCSRgbR3bx-AoJCgJC3a1rahJilsuSYsoEgGhXtTQilQqIcTlYcbHdhcor4AjKjYzmv__51vMXEZzlWqFIXSV4EVCJE25Xqo3FpV8MMTiBVQQiaYJGEvyHCrgoqoJqi6rl9BCve6aGIta7mOpgP5MJ62HzKpWbFp7ee3BC7PsWrThVivTSTvd_ZV8DXk7BO8Q_AMIDsD_Af4OBH2-scUPf8bRuzj6yNd62eYgz8TR77S7B14H_BZ4x0mnF4_Wz1Y3cisJmrz_HbyjrLl-jj19NVsZtZPB52Rll7eP0u4w7ZxkzXGy_ykLonj85WxlmG6tzmLjVjIapMNTPt4B_y1__SYedcDrgbcN_tp08oGH75PNKNv7NsP6YR4ALwT_GIJtCCYQtNJ-N90_uYIuOrRcZwvnfR49vn3r0dJdYfn-nXtLN5eFEiGYCqItiyZzLL2oOdTWdY3YTFYpJZhZDtVt3dIlx3JkQpluU8WWsGSpRFFF22SmqUrSPLrxj5v_hD5hxvOa-yy_r0FrDdcqMyOXDQUbZFbE4n_ZekprRolKfwG4kOJn |
| ContentType | Journal Article |
| Copyright | 2025 一般社団法人 日本移植学会 |
| Copyright_xml | – notice: 2025 一般社団法人 日本移植学会 |
| DOI | 10.11386/jst.60.1_25 |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2188-0034 |
| EndPage | 37 |
| ExternalDocumentID | article_jst_60_1_60_25_article_char_ja |
| GroupedDBID | 5GY ALMA_UNASSIGNED_HOLDINGS JSF KQ8 MOJWN OK1 RJT |
| ID | FETCH-LOGICAL-j110a-2d42befc958fad9981de47aa10ecfa9d9c93fcf41ae9da6d303c71672dbebb733 |
| ISSN | 0578-7947 |
| IngestDate | Mon Sep 01 00:08:24 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Language | Japanese |
| License | https://creativecommons.org/licenses/by-nc-nd/4.0/deed.ja |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j110a-2d42befc958fad9981de47aa10ecfa9d9c93fcf41ae9da6d303c71672dbebb733 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jst/60/1/60_25/_article/-char/ja |
| PageCount | 13 |
| ParticipantIDs | jstage_primary_article_jst_60_1_60_25_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2025 |
| PublicationDateYYYYMMDD | 2025-01-01 |
| PublicationDate_xml | – year: 2025 text: 2025 |
| PublicationDecade | 2020 |
| PublicationTitle | 移植 |
| PublicationTitleAlternate | 移植 |
| PublicationYear | 2025 |
| Publisher | 一般社団法人 日本移植学会 |
| Publisher_xml | – name: 一般社団法人 日本移植学会 |
| References | 45) Kanda Y. Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant 2013; 48 (3): 452-458. 10) Cruzado JM, Moreno P, Torregrosa JV, et al. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism. J Am Soc Nephrol 2016; 27 (8): 2487-2494. 15) Borchhardt KA, Heinzl H, Mayerwöger E, et al. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008; 86 (7): 919-924. 11) Finnerty BM, Chan TW, Jones G, et al. Parathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival. Surgery 2019; 165 (1): 129-134. 27) Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26 (4): 1327-1339. 7) Egbuna OI, Taylor JG, Bushinsky DA, et al. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007; 21 (4): 558-566. 30) Akizawa T, Ikejiri K, Kondo Y, et al. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial 2020; 24 (3): 248-257. 13) Parikh S, Nagaraja H, Agarwal A, et al. Impact of post-kidney transplant parathyroidectomy on allograft function. Clin Transplant 2013; 27 (3): 397-402. 47) Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2005; 20 (1): 167-175. 50) Hiramitsu T, Tomosugi T, Okada M, et al. Pre-operative Localisation of the Parathyroid Glands in Secondary Hyperparathyroidism: A Retrospective Cohort Study. Sci Rep 2019; 9 (1): 14634. 24) Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13 (4): 1017-1024. 26) Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68 (4): 1793-1800. 23) Walkenhorst Z, Maskin A, Westphal S, et al. Factors Associated With Persistent Post-transplant Hyperparathyroidism After Index Renal Transplantation. J Surg Res 2023; 285: 229-235. 8) Moore J, Tomson CR, Tessa Savage M, et al. Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. Clin Transplant 2011; 25 (3): 406-416. 20) Kirnap NG, Kirnap M, Sayin B, et al. Risk Factors and Treatment Options for Persistent Hyperparathyroidism After Kidney Transplantation. Transplant Proc 2020; 52 (1): 157-161. 28) Akizawa T, Kurita N, Mizobuchi M, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 2016; 6: 19612. 48) Lim JH, Jeon Y, Kim DG, et al. Effect of pretransplant dialysis vintage on clinical outcomes in deceased donor kidney transplant. Sci Rep 2022; 12 (1): 17614. 14) Schneider R, Kolios G, Koch BM, et al. An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective. Surgery 2010; 148 (6): 1091-1099. 6) Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013; 17 (3): 247-288. 9) Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg 2017; 104 (7): 804-813. 33) Cianciolo G, Tondolo F, Barbuto S, et al. A roadmap to parathyroidectomy for kidney transplant candidates. Clin Kidney J 2022; 15 (8): 1459-1474. 36) Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53 (6): 982-992. 17) Littbarski SA, Kaltenborn A, Gwiasda J, et al. Timing of parathyroidectomy in kidney transplant candidates with secondary hyperparathryroidism: effect of pretransplant versus early or late post-transplant parathyroidectomy. Surgery 2018; 163 (2): 373-380. 5) Tang JA, Friedman J, Hwang MS, et al. Parathyroidectomy for tertiary hyperparathyroidism: A systematic review. Am J Otolaryngol 2017; 38 (5): 630-635. 21) Hong N, Lee J, Kim HW, et al. Machine Learning-Derived Integer-Based Score and Prediction of Tertiary Hyperparathyroidism among Kidney Transplant Recipients: An Integer-Based Score to Predict Tertiary Hyperparathyroidism. Clin J Am Soc Nephrol 2022; 17 (7): 1026-1035. 40) Pencina MJ, D’Agostino RB, Sr., D’Agostino RB, Jr., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27 (2): 157-172; discussion 207-212. 29) Blair HA. Etelcalcetide: First Global Approval. Drugs 2016; 76 (18): 1787-1792. 41) Pencina MJ, D’Agostino RB, Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30 (1): 11-21. 19) Yamamoto T, Tominaga Y, Okada M, et al. Characteristics of Persistent Hyperparathyroidism After Renal Transplantation. World J Surg 2016; 40 (3): 600-606. 3) Okada M, Tominaga Y, Sato T, et al. Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia. BMC Nephrol 2022; 23 (1): 212. 16) Seager CM, Srinivas TR, Flechner SM. Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Ann Transplant 2013; 18: 31-35. 22) Sutton W, Chen X, Patel P, et al. Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients. Surgery 2022; 171 (1): 69-76. 4) Fraser WD. Hyperparathyroidism. Lancet 2009; 374 (9684): 145-158. 32) Palmer SC, Mavridis D, Johnson DW, et al. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis 2020; 76 (3): 321-330. 25) Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14 (3): 575-583. 49) Pirklbauer M, Bushinsky DA, Kotanko P, et al. Personalized Prediction of Short- and Long-Term PTH Changes in Maintenance Hemodialysis Patients. Front Med (Lausanne) 2021; 8: 704970. 35) Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4 (5893): 643-646. 31) Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5 (12): 2305-2314. 1) Pihlstrøm H, Dahle DO, Mjøen G, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation 2015; 99 (2): 351-359. 18) Okada M, Hiramitsu T, Ichimori T, et al. Comparison of Pre- and Post-transplant Parathyroidectomy in Renal Transplant Recipients and the Impact of Parathyroidectomy Timing on Calcium Metabolism and Renal Allograft Function: A Retrospective Single-Center Analysis. World J Surg 2020; 44 (2): 498-507. 37) Uemura O, Nagai T, Ishikura K, et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol 2014; 18 (4): 626-633. 42) Alba AC, Agoritsas T, Walsh M, et al. Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature. JAMA 2017; 318 (14): 1377-1384. 2) Araujo M, Ramalho JAM, Elias RM, et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery 2018; 163 (5): 1144-1150. 43) Pencina MJ, D’Agostino RB, Sr. Evaluating Discrimination of Risk Prediction Models: The C Statistic. JAMA 2015; 314 (10): 1063-1064. 46) Tominaga Y, Kakuta T, Yasunaga C, et al. Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons’ Society of Japan. Ther Apher Dial 2016; 20 (1): 6-11. 44) Babu GJ. Resampling methods for model fitting and model selection. J Biopharm Stat 2011; 21 (6): 1177-1186. 12) Schwarz A, Rustien G, Merkel S, et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22 (2): 584-591. 34) Yalla N, Bobba G, Guo G, et al. Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status. J Endocrinol Invest 2019; 42 (11): 1353-1360. 38) Akizawa T, Shimazaki R, Fukagawa M. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS One 2018; 13 (10): e0204896. 39) Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 2017; 317 (2): 156-164. |
| References_xml | – reference: 8) Moore J, Tomson CR, Tessa Savage M, et al. Serum phosphate and calcium concentrations are associated with reduced patient survival following kidney transplantation. Clin Transplant 2011; 25 (3): 406-416. – reference: 38) Akizawa T, Shimazaki R, Fukagawa M. Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study. PLoS One 2018; 13 (10): e0204896. – reference: 6) Fukagawa M, Yokoyama K, Koiwa F, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial 2013; 17 (3): 247-288. – reference: 36) Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009; 53 (6): 982-992. – reference: 2) Araujo M, Ramalho JAM, Elias RM, et al. Persistent hyperparathyroidism as a risk factor for long-term graft failure: the need to discuss indication for parathyroidectomy. Surgery 2018; 163 (5): 1144-1150. – reference: 47) Goldfarb-Rumyantzev A, Hurdle JF, Scandling J, et al. Duration of end-stage renal disease and kidney transplant outcome. Nephrol Dial Transplant 2005; 20 (1): 167-175. – reference: 10) Cruzado JM, Moreno P, Torregrosa JV, et al. A Randomized Study Comparing Parathyroidectomy with Cinacalcet for Treating Hypercalcemia in Kidney Allograft Recipients with Hyperparathyroidism. J Am Soc Nephrol 2016; 27 (8): 2487-2494. – reference: 37) Uemura O, Nagai T, Ishikura K, et al. Creatinine-based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol 2014; 18 (4): 626-633. – reference: 16) Seager CM, Srinivas TR, Flechner SM. Development of nephrolithiasis in a renal transplant patient during treatment with Cinacalcet. Ann Transplant 2013; 18: 31-35. – reference: 14) Schneider R, Kolios G, Koch BM, et al. An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective. Surgery 2010; 148 (6): 1091-1099. – reference: 18) Okada M, Hiramitsu T, Ichimori T, et al. Comparison of Pre- and Post-transplant Parathyroidectomy in Renal Transplant Recipients and the Impact of Parathyroidectomy Timing on Calcium Metabolism and Renal Allograft Function: A Retrospective Single-Center Analysis. World J Surg 2020; 44 (2): 498-507. – reference: 26) Cunningham J, Danese M, Olson K, et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68 (4): 1793-1800. – reference: 11) Finnerty BM, Chan TW, Jones G, et al. Parathyroidectomy versus Cinacalcet in the Management of Tertiary Hyperparathyroidism: Surgery Improves Renal Transplant Allograft Survival. Surgery 2019; 165 (1): 129-134. – reference: 25) Quarles LD, Sherrard DJ, Adler S, et al. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 2003; 14 (3): 575-583. – reference: 35) Payne RB, Little AJ, Williams RB, et al. Interpretation of serum calcium in patients with abnormal serum proteins. Br Med J 1973; 4 (5893): 643-646. – reference: 42) Alba AC, Agoritsas T, Walsh M, et al. Discrimination and Calibration of Clinical Prediction Models: Users’ Guides to the Medical Literature. JAMA 2017; 318 (14): 1377-1384. – reference: 12) Schwarz A, Rustien G, Merkel S, et al. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant 2007; 22 (2): 584-591. – reference: 29) Blair HA. Etelcalcetide: First Global Approval. Drugs 2016; 76 (18): 1787-1792. – reference: 50) Hiramitsu T, Tomosugi T, Okada M, et al. Pre-operative Localisation of the Parathyroid Glands in Secondary Hyperparathyroidism: A Retrospective Cohort Study. Sci Rep 2019; 9 (1): 14634. – reference: 1) Pihlstrøm H, Dahle DO, Mjøen G, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation 2015; 99 (2): 351-359. – reference: 49) Pirklbauer M, Bushinsky DA, Kotanko P, et al. Personalized Prediction of Short- and Long-Term PTH Changes in Maintenance Hemodialysis Patients. Front Med (Lausanne) 2021; 8: 704970. – reference: 9) Dulfer RR, Franssen GJH, Hesselink DA, et al. Systematic review of surgical and medical treatment for tertiary hyperparathyroidism. Br J Surg 2017; 104 (7): 804-813. – reference: 15) Borchhardt KA, Heinzl H, Mayerwöger E, et al. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Transplantation 2008; 86 (7): 919-924. – reference: 33) Cianciolo G, Tondolo F, Barbuto S, et al. A roadmap to parathyroidectomy for kidney transplant candidates. Clin Kidney J 2022; 15 (8): 1459-1474. – reference: 48) Lim JH, Jeon Y, Kim DG, et al. Effect of pretransplant dialysis vintage on clinical outcomes in deceased donor kidney transplant. Sci Rep 2022; 12 (1): 17614. – reference: 5) Tang JA, Friedman J, Hwang MS, et al. Parathyroidectomy for tertiary hyperparathyroidism: A systematic review. Am J Otolaryngol 2017; 38 (5): 630-635. – reference: 30) Akizawa T, Ikejiri K, Kondo Y, et al. Evocalcet: A New Oral Calcimimetic for Dialysis Patients With Secondary Hyperparathyroidism. Ther Apher Dial 2020; 24 (3): 248-257. – reference: 3) Okada M, Tominaga Y, Sato T, et al. Elevated parathyroid hormone one year after kidney transplantation is an independent risk factor for graft loss even without hypercalcemia. BMC Nephrol 2022; 23 (1): 212. – reference: 46) Tominaga Y, Kakuta T, Yasunaga C, et al. Evaluation of Parathyroidectomy for Secondary and Tertiary Hyperparathyroidism by the Parathyroid Surgeons’ Society of Japan. Ther Apher Dial 2016; 20 (1): 6-11. – reference: 22) Sutton W, Chen X, Patel P, et al. Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients. Surgery 2022; 171 (1): 69-76. – reference: 7) Egbuna OI, Taylor JG, Bushinsky DA, et al. Elevated calcium phosphate product after renal transplantation is a risk factor for graft failure. Clin Transplant 2007; 21 (4): 558-566. – reference: 41) Pencina MJ, D’Agostino RB, Sr., Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30 (1): 11-21. – reference: 32) Palmer SC, Mavridis D, Johnson DW, et al. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis 2020; 76 (3): 321-330. – reference: 43) Pencina MJ, D’Agostino RB, Sr. Evaluating Discrimination of Risk Prediction Models: The C Statistic. JAMA 2015; 314 (10): 1063-1064. – reference: 39) Block GA, Bushinsky DA, Cheng S, et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 2017; 317 (2): 156-164. – reference: 45) Kanda Y. Investigation of the freely available easy-to-use software ’EZR’ for medical statistics. Bone Marrow Transplant 2013; 48 (3): 452-458. – reference: 20) Kirnap NG, Kirnap M, Sayin B, et al. Risk Factors and Treatment Options for Persistent Hyperparathyroidism After Kidney Transplantation. Transplant Proc 2020; 52 (1): 157-161. – reference: 21) Hong N, Lee J, Kim HW, et al. Machine Learning-Derived Integer-Based Score and Prediction of Tertiary Hyperparathyroidism among Kidney Transplant Recipients: An Integer-Based Score to Predict Tertiary Hyperparathyroidism. Clin J Am Soc Nephrol 2022; 17 (7): 1026-1035. – reference: 19) Yamamoto T, Tominaga Y, Okada M, et al. Characteristics of Persistent Hyperparathyroidism After Renal Transplantation. World J Surg 2016; 40 (3): 600-606. – reference: 4) Fraser WD. Hyperparathyroidism. Lancet 2009; 374 (9684): 145-158. – reference: 28) Akizawa T, Kurita N, Mizobuchi M, et al. PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 2016; 6: 19612. – reference: 40) Pencina MJ, D’Agostino RB, Sr., D’Agostino RB, Jr., et al. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27 (2): 157-172; discussion 207-212. – reference: 31) Komaba H, Nakanishi S, Fujimori A, et al. Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5 (12): 2305-2314. – reference: 24) Goodman WG, Hladik GA, Turner SA, et al. The Calcimimetic agent AMG 073 lowers plasma parathyroid hormone levels in hemodialysis patients with secondary hyperparathyroidism. J Am Soc Nephrol 2002; 13 (4): 1017-1024. – reference: 27) Raggi P, Chertow GM, Torres PU, et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26 (4): 1327-1339. – reference: 34) Yalla N, Bobba G, Guo G, et al. Parathyroid hormone reference ranges in healthy individuals classified by vitamin D status. J Endocrinol Invest 2019; 42 (11): 1353-1360. – reference: 23) Walkenhorst Z, Maskin A, Westphal S, et al. Factors Associated With Persistent Post-transplant Hyperparathyroidism After Index Renal Transplantation. J Surg Res 2023; 285: 229-235. – reference: 44) Babu GJ. Resampling methods for model fitting and model selection. J Biopharm Stat 2011; 21 (6): 1177-1186. – reference: 13) Parikh S, Nagaraja H, Agarwal A, et al. Impact of post-kidney transplant parathyroidectomy on allograft function. Clin Transplant 2013; 27 (3): 397-402. – reference: 17) Littbarski SA, Kaltenborn A, Gwiasda J, et al. Timing of parathyroidectomy in kidney transplant candidates with secondary hyperparathryroidism: effect of pretransplant versus early or late post-transplant parathyroidectomy. Surgery 2018; 163 (2): 373-380. |
| SSID | ssib002821803 ssib058493041 ssib000872161 ssib005879657 ssj0001032185 |
| Score | 2.3772557 |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 25 |
| SubjectTerms | calcimimetics kidney transplantation parathyroidectomy prediction model tertiary hyperparathyroidism |
| Title | （Secondary Publication）移植前のカルシウム受容体作動薬の使用および投与量の情報は腎移植後の三次性副甲状腺機能亢進症の予測精度を向上させる：単施設後ろ向きコホート研究 |
| URI | https://www.jstage.jst.go.jp/article/jst/60/1/60_25/_article/-char/ja |
| Volume | 60 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 移植, 2025, Vol.60(1), pp.25-37 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbxNHFF8huPRSFUHVb-XQOUVL93tmjrP2WoiqlaqCxM3aLx9yoFUJl56wrZQkYOhHAlWp1LSq-BApqEGiaRrTP2a8tjlU-Rf63uxOWBMOwGX1PPPevN_-3vPuvPXM2jA-jGHWbaeebdKM-qZHc8tMLOaZcR7nVpAmtpviL7qffBqcPOOdOuufPXTkm9qqpQuLyYn06-fuK3mVqEIbxBV3yb5EZPcHhQaQIb5whAjD8YViTKIWCRuEsc-xrM1wAVztMZzu5SSiRFAShiQKiIDJY5NEPraj4MJckohICQ4RoRJcLTgkpLor0F2WMm8RTlEA2xBceCRsEu5qoaF0QsJ9EjHCwW-j5kvphC0Exj0iWNXFROWL6ZbQRczQjuOAFSMMzAE5RQBPBwwQGPMVHouEtu5qoXdoR6vnkRBGhD0DjCnGFGBhq5EtNCwZExpz6KAAwMKgchEKZcUJL526eI44oCDCUZitygp4Y3TWqVCnHKB3JIqiJmCL1LAV8w7hDrZwi3BbQxXVOMhPKejAAfllAnChwENQlAuIBQJjSLt4hgSnoqVyUQalqTPBrRKA6yQJG5WA4CkyD8ygwIGWetlzkHz9Rdf5Yqk0AS1vXgFwFVc-9ongqXLJkF1xxv15RTVV2A4oc2QF85eR0FKC-sib86ovJMxTvoAlMYOHYawQKSR7NK9IUwmP9sAnqz8qKzfUq8tazZYhJWUk4XTLSIJDodIZwFbpDOkjyvFBz1dCQ5sdyFXRVJnglTGt3cHhdmjCDa-cUeaqDabUzMS3QtWnIOVfasxcaqv5hF-bmZZvRzo453HVb7AL5xdP4JPitraZeYt8dY1qg1Y7gLofD47f1s24xbO9AHXmEYdSG5dGf_xZvUzDV3zN7He3WW31hs8or62egJqGu1ZVZqln3ZYLBmo1uWZE70EC7B_VkEMdAJ_2V9SqSf7pN4zXq-p8TpR4jxqHFuJjxn97u8v7F9i52gV2b3dlcvuf8e-DYmUgu_dl757s35O9v2TvluxvFNduFPf_Hg1_GA1_Li6vT69vgs5o-O9k7Y7srsresuw-HK-uj7avPrl0DbrG_aVi40_ZfTBduloN-_gKmmyvjDd_HV-8Xaw8mKxtTVYfTZd2xnd_mfaHo53fnlzcmty4hGo7y-PtzcnW42Lnlux9X3z73Wh7VXbXZfem7F3e2_2pGPw4vj6c3vkDh-0NQEF2B7L3UPZvyv6u7C9PNtYmdx8dN860otONk2b1LznmApRuselknpPknZT7rBNnnDM7yz0ax7aVp52YZzzlbifteHac8ywOMqhZUmoH1MmSPEmo675pHD73xbn8LWMuZV7eyTgLXJp73PdiP3A7LE2TJOhYLMjeNvwyOu0vy1chtV8srd55Rbt3jdfwa1w-8X7POLz41YX8fagBF5MPVIL-DzKUiTo |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%EF%BC%88Secondary+Publication%EF%BC%89%E7%A7%BB%E6%A4%8D%E5%89%8D%E3%81%AE%E3%82%AB%E3%83%AB%E3%82%B7%E3%82%A6%E3%83%A0%E5%8F%97%E5%AE%B9%E4%BD%93%E4%BD%9C%E5%8B%95%E8%96%AC%E3%81%AE%E4%BD%BF%E7%94%A8%E3%81%8A%E3%82%88%E3%81%B3%E6%8A%95%E4%B8%8E%E9%87%8F%E3%81%AE%E6%83%85%E5%A0%B1%E3%81%AF%E8%85%8E%E7%A7%BB%E6%A4%8D%E5%BE%8C%E3%81%AE%E4%B8%89%E6%AC%A1%E6%80%A7%E5%89%AF%E7%94%B2%E7%8A%B6%E8%85%BA%E6%A9%9F%E8%83%BD%E4%BA%A2%E9%80%B2%E7%97%87%E3%81%AE%E4%BA%88%E6%B8%AC%E7%B2%BE%E5%BA%A6%E3%82%92%E5%90%91%E4%B8%8A%E3%81%95%E3%81%9B%E3%82%8B%EF%BC%9A%E5%8D%98%E6%96%BD%E8%A8%AD%E5%BE%8C%E3%82%8D%E5%90%91%E3%81%8D%E3%82%B3%E3%83%9B%E3%83%BC%E3%83%88%E7%A0%94%E7%A9%B6&rft.jtitle=%E7%A7%BB%E6%A4%8D&rft.au=%E4%BD%90%E8%97%A4+%E5%93%B2%E5%BD%A6&rft.au=%E6%B8%A1%E4%BA%95+%E8%87%B3%E5%BD%A6&rft.au=%E9%95%B7%E8%B0%B7%E5%B7%9D+%E9%9B%84%E5%9F%BA&rft.au=%E4%B8%80%E6%A3%AE+%E6%95%8F%E5%BC%98&rft.date=2025&rft.pub=%E4%B8%80%E8%88%AC%E7%A4%BE%E5%9B%A3%E6%B3%95%E4%BA%BA+%E6%97%A5%E6%9C%AC%E7%A7%BB%E6%A4%8D%E5%AD%A6%E4%BC%9A&rft.issn=0578-7947&rft.eissn=2188-0034&rft.volume=60&rft.issue=1&rft.spage=25&rft.epage=37&rft_id=info:doi/10.11386%2Fjst.60.1_25&rft.externalDocID=article_jst_60_1_60_25_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0578-7947&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0578-7947&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0578-7947&client=summon |